A groundbreaking new study led by the University of Kentucky Markey Cancer Center's Dr. Peter Zhou found that triple-negative breast cancer cells are missing a key enzyme that other cancer cells contain, providing insight into potential therapeutic targets to treat the aggressive cancer. Zhou's study is unique in that his lab is the only one in the country to specifically study the metabolic process of triple-negative breast cancer cells. Triple-negative breast cancer is the most deadly subtype of breast cancer and has poor clinical outcomes due to the early metastasis of tumor cells, resistance to chemotherapy, and the lack of specific drugs that target it.
Produced by Research Communications at the University of Kentucky.
Loading more stuff…
Hmm…it looks like things are taking a while to load. Try again?